Homburger advised the joint book-running managers in connection with the public offering of an aggregate 7,392,857 common shares in CRISPR Therapeutics AG

On June 30, 2020, CRISPR Therapeutics AG, a leading gene editing company based in Zug, Switzerland, focusing on developing transformative gene-based medicines for serious diseases based on its proprietary CRISPR/Cas9 technology, and each of Goldman Sachs & Co. LLC, BofA Securities, Inc. and Jefferies LLC, as joint book-running managers, and each of Canaccord Genuity LLC, William Blair & Company, L.L.C., SunTrust Robinson Humphrey, Inc. and Roth Capital Partners, LLC, as co-managers, entered into an underwriting agreement relating to the public offering of 6,428,572 common shares at a price of $70.00 per share, before underwriting discounts. On June 30, 2020, the underwriters exercised in full an over-allotment option granted to them under the underwriting agreement to purchase an additional 964,285 common shares in CRISPR Therapeutics AG at the offer price. Comprising an aggregate 7’392’857 common shares in CRISPR Therapeutics AG, the gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, are approximately USD 517.5 m. Each of the base offering and the over-allotment offering closed on July 6, 2020.

Homburger AG acted as legal counsel to Goldman Sachs & Co. LLC, BofA Securities, Inc. and Jefferies LLC as the joint book-running managers and representatives of the several underwriters in the offering. The Homburger team comprised partner Frank Gerhard and associate Lorenzo Togni (both Corporate / M&A and Capital Markets).